Table 3.
Baseline characteristics of 607 thyroid cancer patients undergoing TNM staging
| Characteristics | All | N0 | N1 | Nx |
|---|---|---|---|---|
| n | 607 | 338 | 258 | 11 |
| Gender | ||||
| Male | 118 (19.4%) | 45 (13.3%) | 70 (27.1%) | 3 (27.3%) |
| Female | 489 (80.6%) | 293 (86.7%) | 188 (72.9%) | 8 (72.7%) |
| Age (years) | 46 (35 – 53) | 48 (40 – 54) | 39 (31 – 50) | 51 (36 – 63) |
| Tumor size (mm) | 10.0 (7.0 – 17.0) | 8.8 (6.0 – 13.0) | 13.0 (9.0 – 22.8) | 17.0 (8.0 – 27.0) |
| TgAb (IU/mL) | 2.295 (1.120 – 20.893) | 2.270 (1.120 – 17.670) | 2.290 (1.100 – 34.320) | 3.790 (1.298 – 16.000) |
| TPOAb (IU/mL) | 1.520 (0.578 – 18.705) | 1.820 (0.620 – 30.320) | 1.220 (0.460 – 10.000) | 1.910 (0.625 – 14.088) |
| Pathology | ||||
| PTC | 598 (98.5%) | 335 (99.1%) | 254 (98.4%) | 9 (81.8%) |
| Others | 9 (1.5%) | 3 (0.9%) | 4 (1.6%) | 2 (18.2%) |
CTC circulating tumor cell, TgAb thyroglobulin antibody, TPOAb Thyroid peroxidase antibody, PTC papillary thyroid carcinoma